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Abstract
Background: Current angiogenic therapies for cancers and cardiovascular diseases have not yet achieved expected
benefits, which reflects the need for improved understanding of angiogenesis. In this study, we focused on solving
the problem of whether tissues have different angiogenic potentials (APs) in physiological conditions and how
angiogenesis is regulated in various disease conditions.
Methods: In healthy and diseased human and mouse tissues, we profiled the expression of 163 angiogenic genes,
including transcription regulators (TRs), growth factors and receptors (GF/Rs), cytokines and chemokines (C/Cs), and
proteases and inhibitors (P/Is). TRs were categorized as inflammatory, homeostatic, and endothelial cell-specific TRs,
and C/Cs were categorized as pro-angiogenic, anti-angiogenic, and bi-functional C/Cs.
Results: We made the following findings: (1) the human heart, muscle, eye, pancreas, and lymph node are among
the tissues with the highest APs; (2) tissues with high APs have more active angiogenic pathways and angiogenic
C/C responses; (3) inflammatory TRs dominate regulation of all angiogenic C/Cs; homeostatic TRs regulate all to a
lower extent, while endothelial cell-specific TRs mainly regulate pro-angiogenic and bi-functional C/Cs; (4) tissue AP
is positively correlated with the expression of oxygen sensors PHD2 and HIF1B, VEGF pathway gene VEGFB, and
stem cell gene SOX2; (5) cancers of the digestive system tend to have increased angiogenesis dominated by
endothelial cell-specific pro-angiogenic pathways, while lung cancer and prostate cancer have significantly
decreased angiogenesis; and (6) endothelial cell-specific pro-angiogenic pathways are significantly increased in
thrombus-derived leukocytes in patients with acute coronary artery disease.
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Conclusions: Our results demonstrate that thrombus-derived leukocytes express more endothelial cell-specific
angiogenic markers to directly promote angiogenesis after myocardial infarction and that certain solid tumors may
be more sensitive to anti-angiogenic therapies than others.
Keywords: Angiogenic genes, Tissue expression of genes, Pathological modulation of angiogenesis, Immune
regulation of angiogenesis, Angiogenic leukocytes
Background
Atherosclerosis and its complications, such as myocar-
dial infarction, stroke, and peripheral artery disease
(PAD), are the leading cause of morbidity and mortality
in the world [1]. Tissue damage induced by ischemia
and major artery blockage is one of the major patho-
logical mechanisms underlying these diseases. Thus, de-
velopment of novel therapeutics for re-gaining efficient
blood supply of oxygen and nutrients by regenerating
and remodeling vascular system in the ischemic tissues
hold great promise for treating these life-threatening
diseases [2]. In post-ischemic re-vascularization, the
vascular system develops via the coordinated actions of
several cell types for vasculogenesis [3], angiogenesis [4],
arteriogenesis, and collateral growth [2]. In this study,
we focus on angiogenesis, which is the process of
sprouting new vessels from pre-existing ones [4]. Phy-
siological angiogenesis occurs during development stages
and wound healing, which consists of vessel destabilization,
endothelial cell (EC) migration and proliferation, and
sprouting. This is followed by the resolution phase,
which is characterized by reduced EC proliferation
and stabilization of the new vessel [4].
In ischemic diseases, inflammatory factors and cells
play an important role in the mobilization of angiogenic
cells [5], and the angiogenic process cross-talks with the
inflammation process in many different ways [6]. To
determine whether inflammatory factors assist angio-
genic cells in recognizing cardiovascular disease risk fac-
tors such as hyperlipidemia, hyperglycemia, obesity,
metabolic syndrome, hypertension, smoke, and hyperho-
mocystemia [7], we recently reported a series of findings
on the expression and roles of innate immune/in-
flammation sensor caspase-1/inflammasome [8–10] in
regulating angiogenic cells, including endothelial cell
[11–15], Sca-1+ progenitor cell [16, 17]. We also found
that CD4+Foxp3+ regulatory T cells (Tregs) inhibit vas-
cular inflammation [18–20] and that Treg-generated
newly classified responsive immunosuppressive cyto-
kine interleukin-35 (IL-35) [21] suppresses EC activa-
tion [22]. Also, several angiogenic signaling pathways
such as mitogen-activated protein kinase (MAPK) [23],
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-
protein kinase B (PKB, AKT) [24], NOTCH receptors
(NOTCH1, 2, 3, and 4), NF-κB (nuclear factor kappa B),
and Janus kinase (JAK)-signal transducer and activator
of transcription (STAT) (JAK-STAT) have been identi-
fied in inflammatory conditions [25]. In addition, the
characterization of the roles of a variety of angiogenic
mediators in re-vascularizing the ischemic myocar-
dium has been the focus of two decades of preclinical
research, including vascular endothelial growth factor
(VEGF), fibroblast growth factor, hepatocyte growth
factor.
Although the reports on this front are very encour-
aging, the development of efficiently functioning collat-
eral vessels in the ischemic heart still faces a
multifaceted challenge, including choosing route of de-
livery, dosing levels, relevant animal models, duration of
treatment, and assessment of phenotype for efficacy
[26], which reflect the urgent need to improve our un-
derstanding of the expression and regulation of angio-
genic factors in cells and tissues in physiological and
pathological settings. In this study, we address several
fundamental questions including, first, whether tissues
have different angiogenic potentials (APs) under physio-
logical conditions; second, what the determining factors
for the tissue AP are; and third, how angiogenesis is reg-
ulated in different diseases, especially in cancer and
myocardial infarction. In this study, we hypothesized
that in physiological conditions, tissues have different
APs and programs, and in pathological situations, in-
flammation and immunosuppression regulate ischemic
angiogenesis depending on disease/inflammation set-
tings. To examine this hypothesis, we took a panoramic
profiling on the expression of 163 angiogenic genes in
healthy and diseased human and mouse tissues including
26 transcription factors (TRs), 64 growth factors and re-
ceptors (G/Rs), 27 cytokines and chemokines (C/Cs),
and 46 proteases and inhibitors (P/Is). We found that,
first, the human heart, muscle, eye, lymph node, and
pancreas have the highest tissue APs; second, tissue APs
may be regulated by cell oxygen sensors PHD2 and
HIF1B, VEGF pathway component VEGFB, and stem
cell master gene SOX2; third, angiogenesis is diffe-
rentially regulated in various cancers, chronic metabolic
diseases, and autoimmune diseases; and fourth, thrombus-
derived leukocytes exhibit more EC-specific angiogenic
makers than peripheral blood leukocytes do in acute coron-
ary syndrome patients, which suggests thrombus-derived
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leukocytes may phenotypically switch into EC-like an-
giogenic cells to directly promote angiogenesis. Our
new findings will improve the current understanding
of angiogenesis in healthy and diseased settings and
will eventually lead to novel therapeutics for ischemic
diseases and cancers.
Methods
Tissue expression profiles of angiogenic genes in
physiological conditions
As reported in our previous publications [8], we devel-
oped an experiment-generated data mining strategy
(Fig. 1a) to analyze the messenger RNA (mRNA) expres-
sion of 163 of the most relevant angiogenic genes
(Additional file 1: Table S1) in various human and
mouse tissues based on literature. Expressed sequence
tags (ESTs) from the UniGene Library in National
Center of Biotechnology Information (NCBI) [27]
were used to determine mRNA expression levels in
tissues. Transcripts per million (TPM) of genes of
interest were normalized with those of house-keeping
gene β-actin in each given tissue for comparison
among all tissues. These normalized values were then
normalized with the median of all tissues to calculate
the arbitrary units of gene expression for comparison
among all genes (if the median value is 0, we would
recalculate the median of tissues with TPM > 0). A
confidence interval of the expression variation of
house-keeping genes was generated by calculating the
mean plus two times that of the standard deviations
of the arbitrary units of three randomly selected
house-keeping genes (GAPDH, HPRT1, and GUSB)
normalized by β-actin in the given tissues (Fig. 2). If
the expression variation of a given gene in one tissue
was larger than the upper limit of the confidence
interval of the house-keeping genes, the expression
level of the gene in this tissue was considered high
with statistical significance.
Expression changes of angiogenic genes in pathological
conditions
Gene expression profiles were collected from microarray
datasets in NIH-GEO database (Fig. 1b). Specific sam-
ples were chosen as disease or treatment groups to
compare with their parallel controls by GEO2R [28].
The number of samples was always greater than three.
By searching for the gene symbols from the microarray
data, we selected the genes in our list of 163 angiogenic
genes with significant expression changes (p < 0.05).
The genes of which the expression changes were
greater than or equal to 2-fold were defined as the up-
regulated genes, while genes with their expression
changes less than or equal to 0.5-fold were defined as
downregulated ones.
Fig. 1 Flow chart of database mining strategy and two parts of data organization. a The strategy in generating tissue expression profile of
angiogenic genes in physiological conditions. b The strategy in analysis of angiogenic gene changes in pathological conditions
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Ingenuity pathway analysis (IPA)
Molecular function types of 163 angiogenic genes were
categorized based on IPA database [29] (Additional file 1:
Table S1). Functional interactions and potential physical
interactions between molecules were illustrated using IPA
Path Designer (Fig. 4a and Fig. 6b).
Protein subcellular location
The subcellular localization of protein was determined
using two widely used protein intracellular localization
databases [30], namely COMPARTMENTS subcellular
location database [31] and UniProtKB/Swiss-Prot loca-
tion database (European Bioinformatics Institute). De-
tails can be found in our previous publication [10].
Results
The heart, muscle, eye, lymph node, and pancreas are
among the tissues with the highest APs in humans
We hypothesized that under physiological conditions,
tissues undergo different patterns of angiogenesis, which
are regulated based on their needs for oxygen and nutri-
ents [32]. To examine this hypothesis, an experiment-
generated database mining strategy that we developed
(Fig. 2) [8] was used to examine experimentally verified
expression profiles of mRNA transcripts of 163 an-
giogenic genes (Additional file 1: Table S1) in NCBI-
UniGene database among 22 human tissues and 18
mouse tissues (fewer mouse tissues were examined due
to the fact that gene expression data for the four tissue
counterparts in mice were not available in the database).
Based on the functional modes of angiogenic genes, they
were categorized into four groups based on molecular
types in IPA (TRs, GF/Rs, C/Cs, and P/Is). Tissues that
had more genes with high expression levels were consid-
ered as having higher APs in preparation for physio-
logical changes like wound healing and pathological
challenges like ischemia and inflammation. We found
that humans and mice have different tissue patterns in
terms of AP (Fig. 3a), suggesting that specific tissue AP
has been acquired by human tissues as a functional
adaptation during evolution. Interestingly, muscle in hu-
man has the highest AP, which suggests that sufficient
blood supply is highly significant for muscle function,
tissue remodeling, and human survival throughout evo-
lution. Among the 18 common tissues shared in humans
and mice, muscle, eye, pancreas, and lymph node are the
tissues with the highest APs (Fig. 3b). The heart has high
AP in humans and moderate AP in mice. We then com-
pared the composition (percentages of four groups) of
highly expressed genes among heart and the nine other
tissues shared by humans and mice in Fig. 3c. Again, we
find the differences of composition patterns in these
Fig. 2 Method of analyzing tissue EST profile. a Data presentation format as presented in X-axis and Y-axis and tissue order is applied to all the
genes examined. As an example, the gene expression profile of human house-keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH
Hs.544577) in 22 human tissues is shown. The gene expression data was normalized by the β-actin (Hs. 520640) expression data from the same
tissue, which is presented on the left Y-axis. The arbitrary unit for comparing gene expression level among all tissues was generated by normalizing
the gene expression data (after normalization by β-actin) in the tissue with the median expression level among all the tissues, which is presented on
the right Y-axis. In order to define confidence interval for statistically high expression level of a given gene, we calculated the mean of confidence
intervals [mean (X) + 2 × standard deviations (SD) = 3.63] of three randomly chosen house-keeping genes including GAPDH, hypoxanthine
phosphoribosyltransferase 1 (HPRT1 Hs.412707), and glucuronidase, beta (GUSB Hs.255230). The expression variations of given genes in
tissues, when they were larger than 3.63-fold, were defined as the high expression levels with statistical significance (the right Y-axis). In
this example, GAPDH is highly expressed in muscle. b Same strategy applies to mouse genes among 18 tissues. The mean of [X + 2 × SD= 4.12] was
determined as the confidence interval for mouse genes expression
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Fig. 3 The human heart, muscle, lymph node, eye, and pancreas are among the tissues with the highest angiogenic potentials. a Percentage of
highly expressed genes among 18 mouse tissues and 22 human tissues indicating angiogenic potentials. We analyzed 163 genes related to
angiogenesis, including 26 transcription regulators (16%), 64 growth factors and receptors (39%), 27 cytokines and chemokines (17%), and 46
proteases, inhibitors and others (28%). b Three tiers of tissues based on angiogenic potentials among 18 common tissues in human and mouse.
The highest six tissues in each species are considered with high angiogenic potential, then the middle six tissues, and the lowest six tissues with
low angiogenic potential. c Comparison of contributors for angiogenic potentials between human and mouse. The heart and nine overlapped
tissues in Fig. 3b are compared for the composition of highly expressed genes in terms of the four groups of angiogenic genes. In each tissue,
the right bar stands for human, and the left bar stands for mouse
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tissues between humans and mice. Interestingly, APs are
positively correlated with the percentages of TRs among
highly expressed genes, but not GF/Rs, C/Cs, or P/Is, em-
phasizing that TRs are the master genes in regulating tis-
sue APs. These results suggest that under physiological
conditions, the muscle, eye, lymph node, pancreas, and
human heart have already been conditioned with high
APs enabling their recovery from pathophysiological in-
sults like wound healing, ischemia, and inflammation.
Tissues with high angiogenic potentials are substantiated
with more active angiogenic pathways and angiogenic
cytokine/chemokine responses under physiological
conditions
Pathological angiogenesis often involves inflammatory
conditions such as tumor angiogenesis and ischemia-
induced angiogenesis [25]. As aforementioned, the five
most relevant signaling pathways are activated under
chronic inflammation, MAPK, PI3K-AKT, NOTCH, NF-
κB, and JAK-STAT. We also included two key EC-
specific pathways regulating angiogenesis, HIF-VEGF
and angiopoietin-tyrosine kinase with immunoglobulin-
like and EGF-like domains (ANG-TIE) [33]. Based on
the method we developed (Fig. 2), key molecules in each
signaling pathway that are most relevant to angiogenesis
were examined to determine the activity of each pathway
under physiological conditions (Table 1). We determined
that if tissues have more than or equal to (≥) 1/3 of
pathway-specific angiogenic genes (listed in Table 1) that
are highly expressed, these pathways are considered ac-
tive in those tissues. Similarly, if tissues have more than
two active signaling pathways out of the seven pathways,
these tissues are considered as having active angiogenic
signaling. As shown in Table 2, we found that the hu-
man lymph node and muscle are the two tissues having
more active global angiogenic signaling in humans than
other tissues. A lymph node has two important active
pathways, NF-κB and JAK-STAT, which respond to in-
flammatory stimuli in both humans and mice, while
muscle has two key EC-specific active pathways, HIF-
VEGF and ANG-TIE, in humans. In mice, the eye, lymph
node, spleen, and thymus have more active angiogenic sig-
naling than other tissues. Interestingly, in both humans and
mice, immune organs tend to have more active pathways
responding to inflammation than others, whereas non-
immune organs such as the muscle, eye, heart, and pan-
creas have more active EC-specific pathways.
Immunotherapy has been developed to treat chronic
inflammatory diseases. Thus, we also examined the
expression levels of 27 C/Cs, which are most relevant
to angiogenesis [34], in different tissues under phy-
siological conditions. Based on the C/Cs roles in
modulating angiogenesis, these C/Cs were classified
into three categories, pro-angiogenic, anti-angiogenic,
and bi-functional (Tables 3 and 4). C/Cs highly expressed
in more than median numbers of tissues among all are
considered as abundant C/Cs. We found that human
CCL5, IL-15, and IL-6 are among the most abundant pro-
angiogenic C/Cs in tissues. In contrast, CXCL9 and
CXCL14 are the most abundant anti-angiogenic C/Cs. IL-
18 is the most abundant human bi-functional C/C. In
mice, Ccl2 and Il-15 are the most abundant pro-
angiogenic C/Cs; Cxcl11, Cxcl14, and Pf4 are the most
abundant anti-angiogenic C/Cs; and Cxcl16 is the most
abundant bi-functional C/C. We consider that tissues with
more than median numbers of C/Cs being highly
expressed among all have high angiogenic C/C responses.
We found that the human heart, muscle, eye, pancreas,
bone, kidney, liver, and lung are the tissues more likely to
develop high angiogenic C/C responses (Table 3); while
the mouse eye, lymph node, muscle, spleen, liver, and thy-
mus are the tissues with high angiogenic C/C responses
(Table 4). Interestingly, we also found that in humans,
more pro-angiogenic C/Cs are highly expressed, while
mice have more anti-angiogenic C/Cs highly expressed.
This may explain the potential differences between human
diseases and mouse models studying angiogenesis.
Taken together, these results suggest that the tissues with
high APs based on tissue expression of 163 angiogenic genes
also have more active pro-angiogenic pathways and stronger
C/Cs responses; these angiogenic C/Cs probably are the me-
diators signaled via the seven angiogenic pathways.
Table 1 Seven pro-angiogenic pathways are included in this study
Pathways ID Number of genes Gene symbol
MAPK (1) 6 ETS1 JUN MAPK1 MAPK8 MAPK14 MAP4K4
PI3K-AKT (2) 8 AKT1 FOXO1 FOXO3 PIK3CA PIK3CB PIK3CD PIK3CG PTEN
NOTCH (3) 10 DLL1 DLL3 DLL4 JAG1 JAG2 NOTCH1 NOTCH2 NOTCH3 NOTCH4 RBPJ
NF-κB (4) 5 NFKB1 NFKB2 REL RELA RELB
JAK-STAT (5) 4 CISH JAK2 STAT1 STAT3
HIF-VEGF (6) 14 ARNT EGLN1 EPAS1 FIGF FLT1 FLT4 HIF1A KDR NRP1 NRP2 PGF VEGFA VEGFB VEGFC
ANG-TIE (7) 6 ANGPT1 ANGPT2 ANGPTL3 ANGPTL4 TEK TIE1
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Inflammatory transcription regulators (TRs) dominate
regulation of all angiogenic cytokines/chemokines (C/Cs);
homeostatic TRs regulate all to a lower extent, while
endothelial cell-specific TRs mainly regulate pro-
angiogenic and bi-functional C/Cs
We found that TRs serve as master genes in determining
tissue APs in physiological conditions (Fig. 3c). To deter-
mine how these seven angiogenic pathways regulate
angiogenic C/Cs under pathophysiological conditions,
we used the IPA Path Designer to illustrate the interac-
tions between 19 TRs in the seven pro-angiogenic path-
ways and 27 angiogenic C/Cs based on published
literatures (Fig. 4a). We found three major groups of
TRs that regulate angiogenesis differentially in various
pathophysiological settings: first, inflammatory TRs [35]
are the main regulators of all three groups of C/Cs, and
on average, each inflammatory TR can regulate 43.6% of
pro-angiogenic C/Cs, 47.1% of anti-angiogenic C/Cs,
and 51.7% of bi-functional C/Cs, suggesting that inflam-
matory TRs may function differently in different phases
of inflammation; second, homeostatic TRs can also regu-
late all three groups of angiogenic C/Cs, albeit to a lesser
extent compared to inflammatory TRs (on average, each
TR can regulate 20.0% of pro-angiogenic, 14.3% of anti-
angiogenic, and 35.0% of bi-functional C/Cs); and third,
EC-specific TRs in HIF-VEGF pathway mainly regulate
pro-angiogenic C/Cs and bi-functional C/Cs (on average,
each TR can regulate 19.3% of pro-angiogenic, 4.3% of
anti-angiogenic, and 21.7% of bi-functional C/Cs) (Fig. 4b).
These results demonstrated that pro-angiogenic TRs are
specifically regulating angiogenic C/Cs. Temporally, dur-
ing acute ischemic conditions, inflammatory regulators
initially dominate the local environment. After intense in-
flammation fades, tissue repair and regeneration, includ-
ing angiogenesis, can be eventually observed [36]. Thus,
inflammatory TRs may regulate different angiogenic C/Cs
in angiogenic cells during the mobilizing phase and
vessel-building phase during pathogenesis.
APs among human tissues are positively correlated with
tissue expression levels of cell oxygen sensors PHD2 and
HIF1B, VEGF pathway component VEGFB, and stem cell
master gene SOX2
To address the question of what factors could determine
tissue APs, we hypothesized that tissue APs are posi-
tively correlated with the tissue expression levels of cell
oxygen sensors. To examine this hypothesis, simple
linear regression analyses were performed by plotting
Table 2 Muscle and lymph node have more active angiogenic pathways in humans: angiogenic pathway expression profiles in 18
common human and mouse tissues
Number in the table stands for the percentage of genes being highly expressed in a specific pathway. Pathways with more than or equal to 1/3 of genes being
highly expressed in individual tissue are considered as active pathways (highlighted in red). Tissues with more than two among the seven pathways being active
are considered tissues with high angiogenic potentials (text is in red)
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mRNA relative expression levels of PHD2 (EGLN1),
HIF1A, HIF2A (EPAS1), and HIF1B (ARNT) against the
percentages of highly expressed genes in each tissue
(based on total 163 genes). We found that the mRNA
relative expression levels of all four genes could indicate
tissue APs in humans (Fig. 5a). Interestingly, expression
levels of PHD1 (EGLN2) and PHD3 (EGLN3) did not
correlate with tissue APs (data not shown). Since VEGF
pathway components are key effectors in mediating
angiogenesis [3], in addition to the oxygen sensors, we
also examined the correlation of VEGFs/VEGFRs mRNA
expression levels with tissue APs (Fig. 5a). We found
that the expression levels of VEGFB, PGF, VEGFR1
(FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4) are posi-
tively correlated with tissue APs. Since tissue repair and
regeneration processes largely rely on angiogenesis, we
also determined whether the expression of stem cell
master genes including CD34, KIT, MYC, KLF4, OCT4
(POUSF1), and SOX2 are positively correlated with tis-
sue APs. Of note, MYC, KLF4, OCT4, and SOX2 are the
induced pluripotent stem (IPS) cell transcription factors
or Yamanaka’s re-programming transcription factors
[37]. Interestingly, the results showed that among the
seven stem cell master genes examined, the expression
levels of KIT (r2 = 0.2724; p < 0.05) and SOX2 (r2 > 0.4;
p < 0.05) are positively correlated with tissue APs
(Fig. 5b). Based on the different correlation factor r2-
between the expression levels of angiogenic genes and
tissue APs, we categorized three types of angiogenic
regulators into three levels of correlation factor r2, high,
middle, and low (Fig. 5b). The results suggest that the
APs among human tissues have high correlation with
the tissue expression levels of cell oxygen sensors
PHD2 and HIF1B, VEGF pathway component VEGFB,
and stem cell master gene SOX2, moderate correlation
with the tissue expression levels of PGF and FLT4, and
low correlation with the tissue expression levels of
HIF1A, HIF2A, KDR, FLT1, and KIT.
To further understand how these angiogenic regula-
tors indicate tissue APs, we categorized 163 genes into
Table 3 Cytokines/chemokines expression profile in human tissues
IDs for 22 human tissues are the same as Fig. 2a. mRNA relative expression levels of C/Cs higher than threshold are texted red. C/Cs highly expressed in more
than the median number of tissues among all are considered as abundant C/Cs (red text). Tissues with more than median number of C/Cs being highly expressed
among all are considered as tissues with high angiogenic responses (red text)
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four groups of angiogenic genes (TRs, GF/Rs, C/Cs, and
P/Is) and found that (1) the expression of VEGFB posi-
tively correlates with APs of all four groups of genes; (2)
the expression levels of HIF1B and PHD2 positively cor-
relate with APs of TRs, GF/Rs, and P/Is; and (3) the ex-
pression level of SOX2 positively correlates with APs of
TRs and GF/Rs (Additional file 1: Figure S1). These re-
sults suggest that different AP master genes are associ-
ated with the expression of specific groups of angiogenic
genes in regulating tissue angiogenesis.
Cancers in digestive system tend to have increased
angiogenesis dominated by EC-specific pro-angiogenic
pathways, while lung cancer and prostate cancer have
significantly decreased angiogenesis
Anti-angiogenic therapy has been suggested as an ap-
proach to treat cancers decades ago [32]. The underlying
rationale, stating that solid tumor expansion is dependent
on blood supply, has been universally accepted. Many
drugs targeting angiogenesis have been developed or are
under clinical trials. However, the clinical outcomes from
patients treated with anti-angiogenic drugs are less sa-
tisfactory than expected [38]. There are no good mechan-
istic explanations on why this discrepancy exists. We
hypothesize that cancers from different tissues have dis-
tinct angiogenic pathways and C/C responses. To test this
issue, we examined seven most relevant pro-angiogenic
pathways including MAPK, PI3K-AKT, NOTCH, NF-κB,
JAK-STAT, HIF-VEGF, and ANG-TIE using the method
that we developed (Fig. 1b). We searched angiogenic gene
expression data in 11 GSE datasets collected in the NIH-
GEO Database (microarray experimental data) on most
common cancers (six types of cancers in digestive system,
three types of cancers in reproductive system, lung cancer
in respiratory system, and lymphoma in lymphoid system)
to better understand the molecular mechanisms under-
lying cancer/tumor angiogenesis (Table 5). In each GSE
dataset, we compared the mRNA expression levels in can-
cer/tumor tissues to their adjacent normal tissues. We
found that digestive cancers have significant gene
Table 4 Cytokines/chemokines expression profile in mouse tissues
IDs for 18 mouse tissues are the same as Fig. 2b. mRNA relative expression levels of C/Cs higher than threshold are texted red. C/Cs highly expressed in more
than the median number of tissues among all are considered as abundant C/Cs (red text). Tissues with more than median number of C/Cs being highly expressed
among all are considered as tissues with high angiogenic responses (red text)
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expression changes enriched in HIF-VEGF and ANG-TIE
pathways, especially in colorectal, gastric, and intrahepatic
cancers, while in reproductive cancers and lung cancer,
most of the pathways are regulated. Interestingly, pancre-
atic cancer did not show any changes in these seven path-
ways, suggesting that the high AP in pancreas (Fig. 3b) are
equipped to match the high demand for angiogenesis in
both physiological and tumor/cancer pathological condi-
tions. As we know, most cancers have increased angiogen-
esis to supply blood and nutrition for cancer/tumor
growth [38]. Surprisingly, here we found that prostate
cancer, lung cancer, and lymphoma show significantly de-
creased gene expression among most changed pathways.
This could be explained by sufficient oxygen supply for
cancer cells in the lung, T cell-mediated immune tolerant/
anti-inflammatory environment in the lung [39], and in cir-
culating prostate cancer cells [40]. Many C/Cs play indis-
pensable roles in communicating between immune cells,
vascular cells, as well as tumor cells in regulating angiogen-
esis [25]. Thus, we further looked into angiogenesis-
regulatory C/Cs in different disease conditions. We found
that most digestive cancers and ovarian cancer have both
Fig. 4 Transcription regulators differentially mediate angiogenic cytokines/chemokines. a Functional interactions and potential physical
interactions between TRs and C/Cs were illustrated using IPA Path Designer. b Summary of TR-regulated C/Cs in three categories
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pro- and anti-angiogenic C/Cs being upregulated, indicat-
ing that the C/Cs system is in a “fighting” mode (Table 6).
However, in prostate cancer and lung cancer, where we
have shown that they present an anti-angiogenic environ-
ment in the pathway analysis (Table 5), pro-angiogenic C/
Cs are significantly downregulated and anti-angiogenic C/
Cs are upregulated (Table 6). These results suggested that
angiogenic pathways in various cancers are differentially
regulated in different tissue environments and pathological
conditions. In order to specifically target key molecules
during the disease conditions, we would need more precise
and accessible detection systems in identifying the person-
alized angiogenic gene expression profiles for timely and
accurate anti-angiogenic treatments for cancer patients.
Pro-angiogenic pathways are significantly upregulated in
thrombus-derived leukocytes in patients with acute
coronary syndrome, retinopathy, and rheumatoid
arthritis; various subcellular-localized upregulated
angiogenic proteins in thrombus leukocytes are
endothelial cell-specific
Angiogenesis in thrombus has been shown to play a key
role in facilitating thrombus resolution [41, 42]. Hypoxia
and HIF1A are induced in the naturally resolving
thrombus and correlate with increased angiogenic factor
expression. Upregulation of HIF1A enhances thrombus
resolution and angiogenesis [43]. Leukocyte infiltration
is one of the hallmarks during this process. To examine
an important question of whether immune cells can
Fig. 5 Genes that determine angiogenic potentials in human tissues. a Correlation of mRNA relative expression levels of specific genes with
angiogenic potential. Simple linear regression was applied to the mRNA relative expression levels (Y-axis) against angiogenic potentials (X-axis) in
total 163 genes. b Three tiers of master genes determining angiogenic potential. Eleven genes with p < 0.05 were categorized into three tiers
based on r2 value
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directly promote angiogenesis, we compared the angio-
genic gene expression profile of leukocytes isolated from
thrombi from the plaque of acute coronary syndrome
(ACS) patients with that in circulating blood leukocytes.
We found that in ACS (unpublished GEO microarray
dataset GSE19339, deposited on Dec. 4, 2009, and up-
dated on Feb. 24, 2017), thrombus-derived white blood
cells showed significant increase of angiogenic pathways
with as many as 15 angiogenic regulators compared to
peripheral leukocytes (Table 7). Although the research
paper associated with this GEO dataset has not been
published from Dr. Luscher’s team in the University
Hospital Zurich, Switzerland, based on similar publica-
tions on isolation of Tregs [44], CD14+ monocytes and
CD66B+ granulocytes [45] in coronary thrombi of pa-
tients with ACS and microarray profiling [46] from this
highly productive team, we were fully convinced that the
high quality of GSE19339 dataset and related tech-
nologies in coronary thrombus leukocyte isolation and
microarray profiling are trustable. In addition, to
Table 5 Gene expression changes of pro-angiogenic pathways in cancers
Seven master pro-angiogenic pathways including MAPK, PI3K-AKT, NOTCH, NF-κB, JAK-STAT, HIF-VEGF, and ANG-TIE are investigated using the method previously
developed (Fig. 1a). We compared gene expression levels in tumor tissues to adjacent normal tissues among six types of cancers in the digestive system, three
types of cancers in the reproductive system, lung cancer, and lymphoma as shown. Genes with significant expression changes (p < 0.05) are shown here. Red text
stands for upregulation (FC ≥ 2), and green text stands for downregulation (FC ≤ 0.5)
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Table 6 Gene expression changes of cytokines/chemokines in cancers
Twenty-seven cytokines/chemokines are investigated using the method we developed (Fig. 1b). We compared gene expression level in tumor tissues to adjacent
normal tissues among six types of cancers in the digestive system, three types of cancers in the reproductive system, lung cancer, and lymphoma as shown.
Genes with significant expression changes (p < 0.05) are shown here. Red text stands for upregulation (FC ≥ 2), and green text stands for downregulation (FC ≤ 0.5)
Fu et al. Journal of Hematology & Oncology  (2017) 10:74 Page 13 of 21
determine the functional significance of upregulated
genes, we examined the subcellular localization of the 15
upregulated genes including FLT1, NRP1, ANGPTL4,
NRP2, VEGFA, EPAS1, JAG1, TEK, JUN, NOTCH3,
TIE1, KDR, HIF1A, ANGPT2, and PGF using two highly
reliable databases (COMPARTMENTS subcellular
location database and UniProtKB/Swiss-Prot location
database) as we reported [10] (Fig. 6a). As shown in
Table 7, we found that among the upregulated genes,
seven genes encode EC-surface receptors including FLT1
(vascular endothelial growth factor receptor 1), NRP1
(vascular endothelial cell growth factor 165 receptor),
Table 7 Gene expression changes of pro-angiogenic pathways in vascular diseases, metabolic diseases, and autoimmune diseases
Seven master pro-angiogenic pathways including MAPK, PI3K-AKT, NOTCH, NF-κB, JAK-STAT, HIF-VEGF, and ANG-TIE are investigated using the method we devel-
oped (Fig. 1b). We compared gene expression level in different tissues to their parallel controls. Genes with significant expression changes (p < 0.05) are shown
here. Red text stands for upregulation (FC ≥ 2), and green text stands for downregulation (FC ≤ 0.5)
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NRP2 (vascular endothelial cell growth factor 165 recep-
tor 2), KDR (cell surface receptor for VEGFA, VEGFC
and VEGFD) [47], TIE1, TEK, and NOTCH3. Moreover,
EPAS1 and HIF1A are two transcription factors (Fig. 6a)
directly involved in hypoxia-induced gene expression
pathway; homeostatic transcription regulator JUN (Fig. 6a)
is a subunit of the transcription factor AP-1 that was
reported to collaborate with HIF1 to increase gene expres-
sion in response to hypoxia [48, 49]. The remaining five
molecules upregulated in thrombus-derived leukocytes
were all pro-angiogenic factors, including ANGPT2,
ANGPTL4, VEGFA, PGF, and JAG1, which we propose
can stimulate thrombus leukocytes to phenotypically
switch into EC-like angiogenic cells, and thrombus-
Fig. 6 Thrombus leukocytes phenotypically switch into endothelial cell-like angiogenic cell in acute coronary syndrome patients. a Subcellular locations of
upregulated genes among different pathways and cytokines/chemokines in acute coronary artery disease dataset GSE19339 (Tables 6 and 7). b Molecular
interactions between upregulated genes, generated by using IPA Path Designer
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trapped circulating ECs via an autocrine and paracrine
manner, to create a pro-angiogenic niche. However,
peripheral blood leukocytes from ACS patients did not
show the similar changes compared to healthy control
(GSE 61144) (Table 7). We also found that a significant
amount of C/Cs in thrombus-derived leukocytes are
upregulated (Table 8), including 8 out of 14 pro-
angiogenic C/Cs, 3 out of 7 anti-angiogenic ones, and 3
out of 6 bi-functional ones. The information shown in
Fig. 6b suggests that the most upregulated C/Cs can be
directly regulated by the three upregulated TRs (EPAS1,
HIF1A, and JUN). Taken together, these results have dem-
onstrated that thrombus-derived leukocytes exhibit potent
pro-angiogenic phenotype by upregulating (i) EC-specific
cell surface markers and (ii) hypoxia-induced transcription
factor signaling pathways and secreting (iii) angiogenic
factors and (iv) angiogenic C/Cs. These findings suggest
that thrombus leukocytes promote angiogenesis not only
through increasing secretion of angiogenic C/Cs and an-
giogenic factors but also via phenotypical switching into
EC-like angiogenic cells.
We also found that retinopathy and rheumatoid
arthritis (RA) have significant changes in many pro-
angiogenic pathways. However, in the conditions of
chronic inflammation, atherosclerosis, PAD, metabolic
syndrome (MS), type 1 diabetes (T1D), and type 2 dia-
betes (T2D), there are no significant changes in any of
these seven pathways (Table 7), suggesting that low-dose
chronic inflammation does not always have a strong sys-
temic angiogenic stimulation. We also examined the C/
C expression changes among these diseases. We found
that a significant number of C/Cs is upregulated in ret-
inopathy and RA. However, in the chronic inflammatory
diseases, there are little to no changes in C/C expression
(Table 8). Taken together, these results suggest that
diseases with active angiogenic pathways also have
highly active C/C responses for cell-cell communication.
Discussion
Significant progress has been made in characterizing fac-
tors regulating angiogenic pathways related to physiological
and pathological processes [47], which has led to the devel-
opment of preclinical assessment of anti-angiogenic ther-
apies for cancers and other diseases [50]. However,
angiogenic therapies have been less than satisfactory [38].
Thus, the development of efficient therapeutics for various
clinical settings for inhibiting cancer/tumor growth and
improving angiogenesis for re-gaining blood supply in is-
chemic heart and ischemic brain areas after stroke still
faces multifaceted challenges [26], which reflect the urgent
need for improving our understanding of the expression
and regulation of angiogenic factors in cells and tissues in
physiological and pathological settings. In this study, we
examined the expression of 163 angiogenesis-regulatory
genes in various tissues in humans and mice in physio-
logical settings and in various pathological processes. We
have made the following significant findings: (1) the heart,
muscle, eye, lymph node, and pancreas are among the tis-
sues with the highest APs in humans; (2) tissues with high
angiogenic potentials have more active angiogenic path-
ways and angiogenic C/C responses under physiological
conditions; (3) inflammatory TRs dominate regulation of
all angiogenic C/Cs, and homeostatic TRs regulate all to a
lower extent, while endothelial cell-specific TRs mainly
regulate pro-angiogenic and bi-functional C/Cs; (4) APs
among human tissues are positively correlated (r2 > 0.4)
with tissue expression levels of cell oxygen sensors PHD2
and HIF1B, VEGF pathway component VEGFB, and stem
cell master gene SOX2; (5) cancers in digestive system tend
to have increased angiogenesis dominated by EC-specific
pro-angiogenic pathways, while lung cancer and prostate
cancer have significantly decreased angiogenesis; and (6)
pro-angiogenic pathways are significantly upregulated in
thrombus-derived leukocytes in patients with acute coron-
ary syndrome, retinopathy, and rheumatoid arthritis, and
various subcellular-localized upregulated angiogenic pro-
teins in thrombus leukocytes are EC-specific. Our novel
findings have provided significant insights into molecular
mechanisms in regulating angiogenesis in various tissue
physiological and pathological processes.
In determining the master regulators for tissue angiogen-
esis, two important issues, which are also related to tissue
regenerative potential, have never been addressed: first,
whether various tissues have differences in angiogenesis
and second, what determines tissue AP if there are differ-
ences. As we know, all eukaryotic organisms rely on oxygen
to support oxidative phosphorylation for efficient adenosine
triphosphate (ATP) production. Therefore, a constant O2
supply, maintained by the vascular system in mammals, is
critical for proper tissue development, homeostasis, and
function. However, the normal physiological O2 concentra-
tion varies greatly among tissues. For example, arterial
blood has a normal partial oxygen pressure (pO2) of 13%,
the myocardium has a pO2 of 10%, and most tissues, in-
cluding the brain, lung, liver, muscle, and bone marrow,
have a pO2 of ~5% [51]. Thus, tissue pO2 levels cannot dir-
ectly serve as master regulator of the expression of angio-
genic genes and therefore tissue AP. To address these
questions, we examined the gene expression levels of 163
angiogenic genes in 22 human tissues and 18 mouse tissues.
We have found that in physiological conditions, significant
positive correlations exist between APs in various tissues
and the tissue expression levels of oxygen sensors PHD2
and HIF1B, VEGF pathway component VEGFB, and stem-
ness gene SOX2 (Fig. 5b). Our results on tissue APs sup-
port current understanding that PHD2, rather than PHD1
or PHD3, is the critical oxygen sensor in normoxia [52].
HIF1B is constitutively expressed, which binds to HIF1A or
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Table 8 Gene expression changes of cytokines/chemokines in vascular diseases, metabolic diseases, and autoimmune diseases
Twenty-seven cytokines/chemokines are investigated using the method we developed (Fig. 1b). We compared gene expression level in different tissues to their parallel
controls. Genes with significant expression changes (p < 0.05) are shown here. Red text stands for upregulation (FC ≥ 2), and green text stands for downregulation (FC≤ 0.5)
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HIF2A to activate transcription of hypoxia-responsive
genes [53]. When tissues with high APs encounter
ischemic conditions, significant downregulation of
PHD2 leads to de-suppression of HIF1A and HIF2A,
which can bind to highly stably expressed HIF1B, and
facilitate these tissues’ initiation of quick and strong angio-
genic response. It has been reported that VEGFB binds
specifically to VEGFR1, which is complex and context-
dependent; and that increased VEGFB expression corre-
lates with cancer stage, tumor multiplicity, and vascular
invasion in multiple cancers [54]. Thus, our new finding
suggests that VEGFB fits well for the angiogenesis indica-
tor. Of note, SOX2 is one of the IPS cell transcription
factors or Yamanaka’s re-programming transcription fac-
tors [37] and can be induced in angiogenic pericytes in
response to hypoxia [55]. In addition, SOX2 functions
with VEGF and drives cancer-initiating stem cells [56, 57].
Our results are the first report showing that tissue expres-
sion level of SOX2, but not of other Yamanaka’s re-
programming transcription factors including MYC, KLF4,
and OCT4, is significantly correlated with tissue APs.
One of the most promising and best studied of anti-
angiogenic therapies utilized to date is bevacizumab, a
humanized monoclonal antibody against VEGFA. Bevacizu-
mab increases survival when added to chemotherapy in
first-line treatment of patients with previously untreated
metastatic colorectal cancer. However, the addition of beva-
cizumab has failed to generate survival advantages for
metastatic disease when added to first-line chemotherapy
at other sites, including metastatic breast, pancreatic, or
ovarian cancer [58, 59]. These results are consistent with
our findings that (1) pro-angiogenic pathways in colorectal
cancer are more EC-specific, while pro-angiogenic path-
ways in breast or ovarian cancers are not and (2) pancreatic
cancer patients show little to no changes in pro-angiogenic
pathways. However, our findings are based on limited data-
sets in different cancer types. To confirm that EC-specific
pathway dominating pro-angiogenic cancers will have bet-
ter response to anti-VEGF therapy, more robust metadata
analyses and experimental studies are needed.
Arterial thrombosis leads to acute ischemic diseases, in-
cluding myocardial infarction, stroke, and PAD. Thrombus
angiogenesis has been shown to play significant roles in
promoting thrombus resolution, which may be a potential
therapeutic strategy [41]. In addition, anti-angiogenic can-
cer therapies have been shown to be associated with a sig-
nificant increase in the risk of arterial thromboembolic
events [60] and venous thromboembolic events [42]. A
meta-analysis of randomized controlled trials showed that
treatment with anti-angiogenic drug bevacizumab might
significantly increase the risk of cardiac ischemic events in
cancer patients; however, the risk of ischemic stroke with
bevacizumab was not significantly different from controls
[61]. Our recent reports have shown that inhibition of
innate immune sensor caspase-1 improves VEGFR signal-
ing, angiogenesis [62], and neovascularization of progeni-
tor cells after myocardial infarction [16]. Inflammatory
and innate immune cells migrated to atherogenic arteries
promote the formation of plaques and thrombi or limit tis-
sue damage and facilitate resolution [63] while athero-
thrombosis, subsequent to plaque rupture or erosion, has
prominent features of inflammation in patients with acute
coronary syndromes [45]. It was reported that monocytes/
macrophages are the most abundant inflammatory cell
types of innate immunity in coronary atherothrombosis
co-expressing Toll-like receptor 4 [45]. Immune cells, in-
cluding Tregs, macrophages, monocytes and dendritic
cells, have been shown to regulate angiogenesis in different
disease settings by providing pro-angiogenic C/Cs and
pro-angiogenic niches [64]. However, other roles of
thrombus leukocytes, outside of the several reported roles
such as triggering thrombosis, causing unstable angina
and myocardial infarction, remain unknown. Thus, we
attempted to address an important question of whether
immune cells can phenotypically switch into EC-like an-
giogenic cells. We compared the angiogenic gene expres-
sion in leukocytes (mainly CD14+ monocytes and CD66B+
granulocytes) [45] isolated from thrombi from the plaque
of ACS patients to that in circulating blood leukocytes.
We found the exciting results that as many as 15 import-
ant angiogenic regulators and 14 angiogenic C/Cs are sig-
nificantly upregulated in thrombus leukocytes in
comparison to those in peripheral blood leukocytes. The
15 upregulated genes include seven EC-surface receptors
for angiogenesis, three hypoxia-response transcription fac-
tors, and other important angiogenic secreting regulators.
Our results have demonstrated for the first time that
thrombus-derived leukocytes can promote angiogenesis not
only through secreting angiogenic C/Cs and angiogenic fac-
tors but also via phenotypical switching into EC-like angio-
genic cells by upregulating EC-specific cell surface markers
and hypoxia-induced transcription factor signaling
pathways. Our findings suggest thrombus-derived leu-
kocytes may trans-differentiate [65] into EC-like an-
giogenic cells, which is similar to Dr. Owens’ team’s
report of trans-differentiated vascular smooth muscle
cell (VSMC)-derived macrophage-like cells in athero-
sclerotic plaques [66].
Our findings are based on a comprehensive database
mining strategy, which allows us to understand angio-
genesis in a broad perspective. However, the limitations
of this study include (1) only transcriptional expression
level was examined in both physiological and patho-
logical conditions and (2) no experimental studies are
available to compare with our proposed findings. To
confirm these findings, further experiments with genet-
ically modified mouse models and genetic lineage tracing
method should be performed.
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Conclusions
To summarize our findings, we propose the following new
working model (Fig. 7): first, angiogenic potentials are var-
ied among tissues, which are found in the highest in the
heart, muscle, eye, lymph node, and pancreas and in the
lowest in bone marrow, skin, thymus, and brain (Fig. 7a);
second, tissue angiogenic potentials may be regulated by
cell oxygen sensors (PHD2, HIF1B, HIF1A, and HIF2A),
VEGF pathway components (VEGFB, PGF, and VEGFR1-
3), and stem cell master genes (SOX2 and KIT) (Fig. 7a);
Fig. 7 New understanding of tissue-specific and disease-specific angiogenesis. a Angiogenic potential in physiological conditions. Master genes
for angiogenic potential are as listed. Font size of gene correlates with its mRNA expression level (PHD2 and HIF1B). b Angiogenesis in
pathological conditions. Font size of pathway name correlates with its gene expression level. Number of C/Cs correlates with their
expression level. c Thrombus leukocytes may trans-differentiate into endothelial cell-like angiogenic cells in ACS patients
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third, angiogenesis is differentially regulated in various
cancers, chronic metabolic diseases, and autoimmune
diseases (Fig. 7b); and fourth, thrombus-derived leuko-
cytes exhibit significantly upregulated EC-specific cell
surface markers, hypoxia-induced transcription factor
signaling pathways, and secrete angiogenesis factors
and C/Cs (Fig. 7c). This also suggests that thrombus
leukocytes promote angiogenesis not only through in-
creasing secretion of angiogenic C/Cs and angiogenic
factors but also via phenotypical switching into EC-
like angiogenic cells. Our novel findings could lead to
new development of future therapeutics for regulating
tissue-specific angiogenesis, tissue regeneration, and
various diseases including cancers and myocardial
infarction.
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